Six‐month BNT162b2 vaccine efficacy in adolescents and young adults with cancer

Abstract

LETTER TO THE EDITOR experiments and the patients and their family for participation in the study. CONFLICT OF INTERESTCaroline Donze, Laetitia Ninove, and Xavier de Lamballerie have no conflict of interest to disclose. Paul Saultier reports receiving support for attending scientific meetings and educational events from Baxalta-Shire, Novo Nordisk, Pfizer, Octapharma, Roche, Servier, and Sobi and has received honoraria (consultant on advisory boards) from Octapharma outside the area of the submitted work. Nicolas Andre reports receiving grants and/or drugs for trials from Bristol Myers Squibb and Pierre Fabre, outside the area of submitted work; receiving travel support from Bristol Myers Squibb; and participating as a scientific advisory board member (without receiving personal fees) for Bayer and Bristol Myers Squibb, and Partners Therapeutics, outside the area of the submitted work. AUTHOR CONTRIBUTIONS Caroline Donze and Paul Saultier wrote the paper. Laetitia Ninove and Xavier de Lamballerie supervised and interpreted the biological analyses. Caroline Donze, Paul Saultier, and Nicolas Andre collected clinical data. Xavier de Lamballerie, Paul Saultier, and NicolasAndre coordinated the study. All authors edited and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Pediatric Cancer Patients Vaccinated Against SARS-CoV-2 – A Clinical and Laboratory Follow-Up

“…Our results are novel, as data on immune responses on SARS-CoV-2 vaccinations in pediatric immunocompromised patients are scarce, in particular regarding data on the long-term follow-up [4,10,14]. Corroborating our results reported previously [10], one retrospective study reported on good e cacy of SARS-CoV-2 vaccination in 13 patients (median age 17 years) receiving chemotherapy for a solid tumor [14].…”

“…Corroborating our results reported previously [10], one retrospective study reported on good e cacy of SARS-CoV-2 vaccination in 13 patients (median age 17 years) receiving chemotherapy for a solid tumor [14]. Donze et al evaluated the anti-SARS-CoV-2 immunity in 4, 17 and 17 pediatric cancer patients receiving one, two and three doses of vaccine, respectively, and assessed the humoral, but not the cellular immune response [4]. When they removed the 11 patients with a documented SARS-CoV-2 infection, the probability of maintaining immunity against SARS-Cov-2 in the 15 patients who had responded to vaccination declined to 50% after 259 days post-vaccination [4].…”

“…Donze et al evaluated the anti-SARS-CoV-2 immunity in 4, 17 and 17 pediatric cancer patients receiving one, two and three doses of vaccine, respectively, and assessed the humoral, but not the cellular immune response [4]. When they removed the 11 patients with a documented SARS-CoV-2 infection, the probability of maintaining immunity against SARS-Cov-2 in the 15 patients who had responded to vaccination declined to 50% after 259 days post-vaccination [4]. In comparison, our study shows a sustained humoral response at the end of the follow-up period which can be explained by the fact that we did not remove patients with a documented SARS-CoV-2 infection, as this re ects the real-life setting.…”

“…It has become clear that children and adolescents receiving therapy for cancer or undergoing hematopoietic cell transplantation are at an increased risk for a severe or even lethal infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5,11]. Whereas the rapid development of vaccines against SARS-CoV-2 and the successful implementation of vaccine programs resulted in the decrease of morbidity and mortality in risk groups such as elderly individuals or in immunocompromised adults [15,16], there is limited information on the effectiveness of SARS-CoV-2 vaccination in pediatric patients on active cancer treatment, and data on the long-term follow up are lacking [4,10,14]. We recently reported on the results of a prospective longitudinal study in 21 pediatric patients receiving chemotherapy for cancer which demonstrated that 3 doses of SARS-CoV-2 mRNA vaccine resulted in both humoral and cellular immunity in most patients [10].…”